Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 42 | 2024 | 11097 | 2.970 |
Why?
|
Leiomyoma | 13 | 2023 | 644 | 2.790 |
Why?
|
Uterine Neoplasms | 15 | 2024 | 1424 | 2.280 |
Why?
|
Ultrasonic Therapy | 10 | 2014 | 216 | 1.490 |
Why?
|
Prostate | 19 | 2023 | 1761 | 1.470 |
Why?
|
Magnetic Resonance Imaging, Interventional | 9 | 2014 | 195 | 1.230 |
Why?
|
Magnetic Resonance Imaging | 41 | 2024 | 36582 | 1.200 |
Why?
|
Gadolinium DTPA | 7 | 2019 | 823 | 1.100 |
Why?
|
Diffusion Magnetic Resonance Imaging | 7 | 2023 | 2811 | 0.810 |
Why?
|
Prostatectomy | 10 | 2021 | 1786 | 0.640 |
Why?
|
Image Interpretation, Computer-Assisted | 10 | 2019 | 3370 | 0.630 |
Why?
|
Leiomyosarcoma | 2 | 2021 | 426 | 0.610 |
Why?
|
Contrast Media | 15 | 2021 | 5329 | 0.590 |
Why?
|
Androgen Antagonists | 2 | 2024 | 1412 | 0.570 |
Why?
|
Leadership | 1 | 2024 | 1394 | 0.480 |
Why?
|
Radiology Information Systems | 2 | 2019 | 535 | 0.480 |
Why?
|
Neoadjuvant Therapy | 4 | 2024 | 2902 | 0.450 |
Why?
|
Uterine Artery Embolization | 2 | 2011 | 62 | 0.450 |
Why?
|
Resilience, Psychological | 1 | 2020 | 807 | 0.410 |
Why?
|
Pilot Projects | 6 | 2024 | 8732 | 0.370 |
Why?
|
Diffusion Tensor Imaging | 1 | 2021 | 2421 | 0.370 |
Why?
|
Sensitivity and Specificity | 12 | 2019 | 14672 | 0.360 |
Why?
|
Fellowships and Scholarships | 2 | 2022 | 1135 | 0.330 |
Why?
|
Reproducibility of Results | 18 | 2019 | 20169 | 0.330 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2011 | 174 | 0.300 |
Why?
|
Therapy, Computer-Assisted | 2 | 2007 | 265 | 0.300 |
Why?
|
Male | 56 | 2024 | 364203 | 0.290 |
Why?
|
Male Urogenital Diseases | 1 | 2008 | 48 | 0.290 |
Why?
|
Radiology | 2 | 2021 | 2106 | 0.290 |
Why?
|
Female Urogenital Diseases | 1 | 2008 | 57 | 0.290 |
Why?
|
Humans | 89 | 2024 | 767040 | 0.280 |
Why?
|
Radiology, Interventional | 1 | 2011 | 483 | 0.280 |
Why?
|
Prostate-Specific Antigen | 6 | 2024 | 2463 | 0.270 |
Why?
|
Sarcoma | 2 | 2024 | 1802 | 0.270 |
Why?
|
Taurine | 2 | 2003 | 91 | 0.240 |
Why?
|
Adenocarcinoma | 3 | 2017 | 6360 | 0.240 |
Why?
|
Education, Medical, Graduate | 1 | 2017 | 2420 | 0.240 |
Why?
|
Neovascularization, Pathologic | 2 | 2019 | 2627 | 0.240 |
Why?
|
Image Enhancement | 5 | 2016 | 2867 | 0.230 |
Why?
|
Pattern Recognition, Automated | 4 | 2016 | 987 | 0.230 |
Why?
|
Curriculum | 1 | 2017 | 3786 | 0.220 |
Why?
|
Negotiating | 1 | 2024 | 152 | 0.210 |
Why?
|
Perineum | 5 | 2019 | 212 | 0.200 |
Why?
|
Models, Biological | 3 | 2019 | 9464 | 0.200 |
Why?
|
Arteries | 3 | 2019 | 1123 | 0.200 |
Why?
|
Watchful Waiting | 2 | 2024 | 492 | 0.190 |
Why?
|
Thiohydantoins | 1 | 2021 | 19 | 0.190 |
Why?
|
Professional Competence | 1 | 2024 | 430 | 0.190 |
Why?
|
Diagnostic Imaging | 6 | 2020 | 3530 | 0.180 |
Why?
|
Middle Aged | 32 | 2022 | 223233 | 0.180 |
Why?
|
Neoplasm Staging | 5 | 2023 | 11217 | 0.180 |
Why?
|
Medical Informatics | 3 | 2020 | 744 | 0.180 |
Why?
|
Job Satisfaction | 1 | 2024 | 548 | 0.180 |
Why?
|
Aged | 27 | 2022 | 171319 | 0.180 |
Why?
|
Motion | 1 | 2023 | 784 | 0.170 |
Why?
|
Diagnosis, Differential | 5 | 2021 | 12986 | 0.170 |
Why?
|
Biopsy | 7 | 2024 | 6777 | 0.160 |
Why?
|
Ascorbic Acid | 1 | 2003 | 658 | 0.160 |
Why?
|
Retrospective Studies | 16 | 2022 | 81659 | 0.160 |
Why?
|
Leuprolide | 1 | 2021 | 313 | 0.160 |
Why?
|
Monitoring, Intraoperative | 1 | 2005 | 947 | 0.160 |
Why?
|
Anisotropy | 1 | 2021 | 1289 | 0.150 |
Why?
|
Neoplasms | 8 | 2017 | 22350 | 0.150 |
Why?
|
Prospective Studies | 8 | 2024 | 54886 | 0.140 |
Why?
|
Hysterectomy | 2 | 2014 | 863 | 0.140 |
Why?
|
Water | 1 | 2023 | 1419 | 0.140 |
Why?
|
Phantoms, Imaging | 2 | 2017 | 2487 | 0.130 |
Why?
|
Androgens | 1 | 2024 | 1281 | 0.130 |
Why?
|
Image Processing, Computer-Assisted | 5 | 2019 | 8940 | 0.130 |
Why?
|
Smoking | 3 | 2003 | 9081 | 0.130 |
Why?
|
Endothelium, Vascular | 3 | 2004 | 4424 | 0.130 |
Why?
|
Prednisone | 1 | 2021 | 1566 | 0.130 |
Why?
|
Faculty, Medical | 1 | 2024 | 1227 | 0.130 |
Why?
|
Oncology Service, Hospital | 1 | 2016 | 55 | 0.130 |
Why?
|
Software | 5 | 2019 | 4472 | 0.130 |
Why?
|
Imaging, Three-Dimensional | 3 | 2013 | 4052 | 0.120 |
Why?
|
Adult | 21 | 2019 | 223317 | 0.120 |
Why?
|
Rectum | 1 | 2019 | 898 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2020 | 9410 | 0.120 |
Why?
|
Algorithms | 8 | 2019 | 14098 | 0.120 |
Why?
|
Organ Size | 2 | 2017 | 2264 | 0.120 |
Why?
|
Liver Neoplasms | 3 | 2012 | 4357 | 0.110 |
Why?
|
Statistics, Nonparametric | 3 | 2011 | 2850 | 0.110 |
Why?
|
High-Intensity Focused Ultrasound Ablation | 1 | 2014 | 43 | 0.110 |
Why?
|
Female | 27 | 2024 | 396660 | 0.110 |
Why?
|
Predictive Value of Tests | 3 | 2019 | 15424 | 0.110 |
Why?
|
Signal Processing, Computer-Assisted | 2 | 2017 | 1458 | 0.110 |
Why?
|
Fiducial Markers | 1 | 2014 | 134 | 0.110 |
Why?
|
Monocytes | 1 | 2003 | 2598 | 0.110 |
Why?
|
Computer Simulation | 3 | 2016 | 6260 | 0.100 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2021 | 1536 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2016 | 11872 | 0.100 |
Why?
|
Tumor Burden | 2 | 2017 | 1903 | 0.100 |
Why?
|
Drug Synergism | 1 | 2016 | 1759 | 0.100 |
Why?
|
Hemodynamics | 1 | 2003 | 4186 | 0.100 |
Why?
|
Radiology Department, Hospital | 1 | 2016 | 409 | 0.100 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1741 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor D | 1 | 2011 | 61 | 0.100 |
Why?
|
Skin Neoplasms | 1 | 2011 | 5859 | 0.090 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2014 | 335 | 0.090 |
Why?
|
Models, Economic | 1 | 2014 | 719 | 0.090 |
Why?
|
Angiomyolipoma | 1 | 2011 | 189 | 0.080 |
Why?
|
Ventricular Function, Left | 1 | 2003 | 3934 | 0.080 |
Why?
|
Ureteral Neoplasms | 1 | 2011 | 106 | 0.080 |
Why?
|
Ultrasonography, Interventional | 3 | 2024 | 1523 | 0.080 |
Why?
|
Efficiency, Organizational | 1 | 2014 | 697 | 0.080 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2013 | 456 | 0.080 |
Why?
|
Treatment Outcome | 9 | 2023 | 65295 | 0.080 |
Why?
|
Metabolomics | 1 | 2019 | 1675 | 0.080 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2014 | 498 | 0.080 |
Why?
|
Quality of Life | 1 | 2011 | 13485 | 0.080 |
Why?
|
Subtraction Technique | 1 | 2012 | 515 | 0.080 |
Why?
|
Urothelium | 1 | 2011 | 275 | 0.080 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2013 | 700 | 0.080 |
Why?
|
Thermography | 1 | 2009 | 62 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 8 | 2017 | 20741 | 0.080 |
Why?
|
Fibromatosis, Aggressive | 1 | 2010 | 125 | 0.080 |
Why?
|
Brachytherapy | 2 | 2014 | 1220 | 0.080 |
Why?
|
Evolution, Molecular | 1 | 2017 | 1893 | 0.080 |
Why?
|
Neoplasm Metastasis | 2 | 2017 | 4892 | 0.080 |
Why?
|
Testicular Neoplasms | 1 | 2014 | 806 | 0.080 |
Why?
|
Cell Lineage | 1 | 2017 | 2575 | 0.070 |
Why?
|
Robotics | 1 | 2014 | 807 | 0.070 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 951 | 0.070 |
Why?
|
Uncertainty | 1 | 2012 | 765 | 0.070 |
Why?
|
Quality-Adjusted Life Years | 1 | 2014 | 1741 | 0.070 |
Why?
|
Lung Neoplasms | 3 | 2017 | 13491 | 0.070 |
Why?
|
Clinical Trials as Topic | 5 | 2016 | 8048 | 0.070 |
Why?
|
Glioblastoma | 2 | 2020 | 3461 | 0.070 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 5389 | 0.070 |
Why?
|
Models, Theoretical | 1 | 2018 | 3561 | 0.070 |
Why?
|
Physicians | 1 | 2024 | 4593 | 0.070 |
Why?
|
Cost-Benefit Analysis | 2 | 2021 | 5537 | 0.070 |
Why?
|
Neoplasm Invasiveness | 2 | 2012 | 3611 | 0.060 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2020 | 300 | 0.060 |
Why?
|
Muscles | 1 | 2011 | 1576 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2783 | 0.060 |
Why?
|
Antineoplastic Agents | 2 | 2021 | 13650 | 0.060 |
Why?
|
Bone Neoplasms | 2 | 2014 | 2563 | 0.060 |
Why?
|
Kidney Neoplasms | 2 | 2011 | 4282 | 0.060 |
Why?
|
Sirolimus | 1 | 2011 | 1539 | 0.060 |
Why?
|
Ultrasonography | 2 | 2014 | 6000 | 0.060 |
Why?
|
Patient Selection | 2 | 2006 | 4256 | 0.050 |
Why?
|
Dermoid Cyst | 1 | 2004 | 92 | 0.050 |
Why?
|
Tuberous Sclerosis | 1 | 2011 | 1039 | 0.050 |
Why?
|
Nitric Oxide Synthase | 2 | 2004 | 911 | 0.050 |
Why?
|
Nitric Oxide Synthase Type III | 2 | 2004 | 706 | 0.050 |
Why?
|
Body Temperature | 1 | 2006 | 780 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2014 | 3468 | 0.050 |
Why?
|
Tomography, Spiral Computed | 1 | 2004 | 273 | 0.050 |
Why?
|
Menstrual Cycle | 1 | 2006 | 546 | 0.050 |
Why?
|
Lipoma | 1 | 2004 | 294 | 0.050 |
Why?
|
Kidney Diseases, Cystic | 1 | 2003 | 182 | 0.050 |
Why?
|
Pravastatin | 1 | 2004 | 393 | 0.050 |
Why?
|
Neoplasms, Second Primary | 1 | 2010 | 1061 | 0.050 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2003 | 153 | 0.050 |
Why?
|
United States | 6 | 2022 | 72971 | 0.050 |
Why?
|
Radiography, Interventional | 1 | 2009 | 1129 | 0.050 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2004 | 329 | 0.050 |
Why?
|
Models, Statistical | 1 | 2016 | 5098 | 0.050 |
Why?
|
Culture Media, Conditioned | 1 | 2003 | 521 | 0.050 |
Why?
|
Endothelin-1 | 1 | 2003 | 296 | 0.050 |
Why?
|
Internship and Residency | 1 | 2021 | 5947 | 0.050 |
Why?
|
Kidney Glomerulus | 1 | 2003 | 571 | 0.050 |
Why?
|
Parental Leave | 1 | 2021 | 92 | 0.040 |
Why?
|
Genomics | 1 | 2016 | 5924 | 0.040 |
Why?
|
Medical Oncology | 1 | 2012 | 2341 | 0.040 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2004 | 594 | 0.040 |
Why?
|
Taxoids | 2 | 2013 | 665 | 0.040 |
Why?
|
Positron-Emission Tomography | 5 | 2013 | 6550 | 0.040 |
Why?
|
Vasodilation | 1 | 2003 | 968 | 0.040 |
Why?
|
Preoperative Period | 1 | 2021 | 564 | 0.040 |
Why?
|
Surgery, Computer-Assisted | 1 | 2006 | 996 | 0.040 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2011 | 2186 | 0.040 |
Why?
|
Policy | 1 | 2021 | 513 | 0.040 |
Why?
|
Hypothermia, Induced | 1 | 2003 | 754 | 0.040 |
Why?
|
Information Dissemination | 2 | 2019 | 1142 | 0.040 |
Why?
|
Peripheral Vascular Diseases | 1 | 2000 | 488 | 0.040 |
Why?
|
Tobacco Use Disorder | 1 | 2003 | 708 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2004 | 21178 | 0.030 |
Why?
|
raf Kinases | 1 | 2016 | 117 | 0.030 |
Why?
|
Limit of Detection | 1 | 2017 | 271 | 0.030 |
Why?
|
Cell Tracking | 1 | 2017 | 139 | 0.030 |
Why?
|
Normal Distribution | 1 | 2016 | 267 | 0.030 |
Why?
|
Mutation | 2 | 2017 | 30211 | 0.030 |
Why?
|
Disease Progression | 3 | 2019 | 13646 | 0.030 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2016 | 252 | 0.030 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 123 | 0.030 |
Why?
|
Cohort Studies | 2 | 2017 | 41718 | 0.030 |
Why?
|
Inflammation | 1 | 2014 | 10869 | 0.030 |
Why?
|
Multiple Myeloma | 1 | 2012 | 5186 | 0.030 |
Why?
|
Nitric Oxide | 1 | 2003 | 2140 | 0.030 |
Why?
|
Aged, 80 and over | 5 | 2014 | 59548 | 0.030 |
Why?
|
Clone Cells | 1 | 2017 | 1669 | 0.030 |
Why?
|
Evaluation Studies as Topic | 1 | 2016 | 1623 | 0.030 |
Why?
|
Genetic Heterogeneity | 1 | 2016 | 735 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7469 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 548 | 0.030 |
Why?
|
Equipment Failure Analysis | 1 | 2014 | 832 | 0.020 |
Why?
|
Kallikreins | 1 | 2013 | 219 | 0.020 |
Why?
|
Antioxidants | 1 | 1999 | 1671 | 0.020 |
Why?
|
Intraoperative Period | 1 | 2012 | 512 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2019 | 2201 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6310 | 0.020 |
Why?
|
Recurrence | 2 | 2014 | 8504 | 0.020 |
Why?
|
Postoperative Care | 1 | 2017 | 1480 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2013 | 638 | 0.020 |
Why?
|
Apoptosis | 2 | 2012 | 9513 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2014 | 1587 | 0.020 |
Why?
|
Research Support as Topic | 1 | 2014 | 697 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2003 | 18989 | 0.020 |
Why?
|
Automation | 1 | 2012 | 587 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2004 | 3449 | 0.020 |
Why?
|
Needles | 1 | 2012 | 461 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1761 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 3249 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8535 | 0.020 |
Why?
|
Molecular Imaging | 1 | 2016 | 822 | 0.020 |
Why?
|
Observer Variation | 1 | 2015 | 2616 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4114 | 0.020 |
Why?
|
Biomedical Research | 2 | 2016 | 3464 | 0.020 |
Why?
|
Breast | 1 | 2017 | 1972 | 0.020 |
Why?
|
Boronic Acids | 1 | 2012 | 915 | 0.020 |
Why?
|
Thoracic Wall | 1 | 2010 | 203 | 0.020 |
Why?
|
Glucose | 1 | 1999 | 4341 | 0.020 |
Why?
|
Cytokines | 1 | 2003 | 7446 | 0.020 |
Why?
|
Safety | 1 | 2012 | 1157 | 0.020 |
Why?
|
Parents | 1 | 2021 | 3594 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2016 | 2061 | 0.020 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2014 | 1233 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2004 | 4903 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2016 | 2883 | 0.020 |
Why?
|
ROC Curve | 1 | 2015 | 3618 | 0.020 |
Why?
|
Thalidomide | 1 | 2012 | 886 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2016 | 2058 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2014 | 2900 | 0.020 |
Why?
|
Databases, Factual | 2 | 2012 | 8068 | 0.020 |
Why?
|
Neutropenia | 1 | 2012 | 892 | 0.020 |
Why?
|
Equipment Design | 1 | 2014 | 3489 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2012 | 2227 | 0.020 |
Why?
|
Pyrazines | 1 | 2012 | 1204 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2016 | 2698 | 0.020 |
Why?
|
Program Development | 1 | 2012 | 1298 | 0.020 |
Why?
|
Treatment Failure | 1 | 2012 | 2658 | 0.020 |
Why?
|
Coronary Disease | 1 | 2000 | 5914 | 0.020 |
Why?
|
Risk Assessment | 2 | 2021 | 24299 | 0.020 |
Why?
|
Dexamethasone | 1 | 2012 | 1963 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2013 | 3552 | 0.010 |
Why?
|
Statistics as Topic | 1 | 2011 | 2350 | 0.010 |
Why?
|
Bayes Theorem | 1 | 2012 | 2353 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2824 | 0.010 |
Why?
|
Medicare | 1 | 2022 | 6813 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2012 | 4855 | 0.010 |
Why?
|
Forecasting | 1 | 2013 | 2936 | 0.010 |
Why?
|
Fallopian Tubes | 1 | 2004 | 179 | 0.010 |
Why?
|
Patient Care Planning | 1 | 2009 | 903 | 0.010 |
Why?
|
Regression Analysis | 1 | 2012 | 6331 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9360 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2017 | 3236 | 0.010 |
Why?
|
Young Adult | 3 | 2014 | 59980 | 0.010 |
Why?
|
Premenopause | 1 | 2006 | 1039 | 0.010 |
Why?
|
Ovariectomy | 1 | 2004 | 612 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2017 | 5332 | 0.010 |
Why?
|
Angiogenesis Inhibitors | 1 | 2012 | 2055 | 0.010 |
Why?
|
Signal Transduction | 2 | 2016 | 23621 | 0.010 |
Why?
|
Time Factors | 1 | 2003 | 40154 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2012 | 2212 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2010 | 2028 | 0.010 |
Why?
|
Sodium Compounds | 1 | 1999 | 35 | 0.010 |
Why?
|
Diuretics, Osmotic | 1 | 1999 | 32 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2010 | 2702 | 0.010 |
Why?
|
Ionophores | 1 | 1999 | 108 | 0.010 |
Why?
|
Radiography | 1 | 2011 | 6975 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2016 | 17097 | 0.010 |
Why?
|
Ovary | 1 | 2004 | 965 | 0.010 |
Why?
|
Arsenites | 1 | 1999 | 65 | 0.010 |
Why?
|
DNA Fragmentation | 1 | 1999 | 238 | 0.010 |
Why?
|
Mannitol | 1 | 1999 | 176 | 0.010 |
Why?
|
Umbilical Veins | 1 | 1999 | 423 | 0.010 |
Why?
|
Phenotype | 1 | 2017 | 16718 | 0.010 |
Why?
|
Osmolar Concentration | 1 | 1999 | 654 | 0.010 |
Why?
|
Risk Factors | 3 | 2014 | 74886 | 0.010 |
Why?
|
Gadolinium | 1 | 2003 | 964 | 0.010 |
Why?
|
Adolescent | 3 | 2014 | 89046 | 0.010 |
Why?
|
Head and Neck Neoplasms | 1 | 2012 | 2930 | 0.010 |
Why?
|
Linear Models | 1 | 2006 | 5875 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2008 | 39317 | 0.010 |
Why?
|
Age Factors | 1 | 2012 | 18401 | 0.010 |
Why?
|
Necrosis | 1 | 1999 | 1614 | 0.010 |
Why?
|
Hyperlipidemias | 1 | 2000 | 771 | 0.010 |
Why?
|
Lung | 1 | 2013 | 10076 | 0.010 |
Why?
|
Up-Regulation | 1 | 2004 | 4143 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2012 | 11657 | 0.010 |
Why?
|
Diabetic Angiopathies | 1 | 1999 | 806 | 0.010 |
Why?
|
Diabetes Complications | 1 | 2000 | 1319 | 0.010 |
Why?
|
Reactive Oxygen Species | 1 | 1999 | 2144 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2012 | 9108 | 0.010 |
Why?
|
Brain | 1 | 2017 | 27163 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 1999 | 3726 | 0.000 |
Why?
|
Homeostasis | 1 | 1999 | 3345 | 0.000 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2000 | 2764 | 0.000 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1999 | 10748 | 0.000 |
Why?
|
Calcium | 1 | 1999 | 5792 | 0.000 |
Why?
|
Exercise | 1 | 2000 | 5954 | 0.000 |
Why?
|
Diet | 1 | 2000 | 8089 | 0.000 |
Why?
|
Hypertension | 1 | 2000 | 8615 | 0.000 |
Why?
|